<DOC>
	<DOCNO>NCT02524054</DOCNO>
	<brief_summary>The purpose protocol develop test aerosol furosemide , treatment potential significantly improve symptom management enhance quality care patient intractable dyspnea .</brief_summary>
	<brief_title>Aerosol Inhalation Treatment Dyspnea - Patients</brief_title>
	<detailed_description>This second study series study investigate treatment effect aerosolize furosemide hospitalize patient outpatient intractable dyspnea . The study focus patient experience intractable dyspnea rest minimal activity , e.g. , dress , bathing , cooking , walk stair short distance . There two part study : Study 2a pilot study 5-10 patient . These trial blind placebo control ; investigator use discover practical problem , take information back laboratory develop solution . Study 2b randomize , placebo - control , double- blind study 25 - 40 patient . The two plan treatment aerosolize furosemide aerosolized saline , give patient two separate day .</detailed_description>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Intractable dyspnea rest minimal activity Chronic congestive heart failure Liver kidney disease Systemic lupus erythematosis ( SLE ) Receiving potassium supplementation indication hypokalemia Major psychiatric disorder Furosemide hypersensitivity Not mentally competent and/or alert ( unable grant inform consent ) Under 18 year old Not fluent English Inadequate birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dyspnea</keyword>
	<keyword>Hospitalized patient</keyword>
	<keyword>Ambulatory outpatient</keyword>
	<keyword>Shortness breath</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>Pulmonary disease</keyword>
</DOC>